A critical roadblock in the development of an HIV-1 vaccine is our current inability to deliver HIV-1 antigens efficiently to the immune system and to prime predictable, high frequency immune responses in humans. Recombinant Ad5 vector-based vaccines have elicited potent immune responses in preclinical studies. However, the high frequency of anti-Ad5 immunity in the developing world will likely substantially limit the immunogenicity and clinical utility of rAd5 vaccines. We therefore propose the development of novel, replication-incompetent rAd vector-based vaccines for HIV-1. The immunogenicity of several novel rAd vaccines will be assessed in rhesus monkeys with anti-Ad5 immunity in Project 1 of this IPCAVD grant, and the optimal vector combination will be advanced into the clinical studies described in this project. We predict that the most immunogenic rAd vaccine regimen will involve two heterologous rAd vectors that are both rare in human populations, engineered for optimal immunogenicity, derived from different Ad subfamilies, and distinct from Ad5. We assume that this will be the rAd35k5-rAd49 prime-boost regimen. Clinical-grade vaccine vectors will be manufactured and regulatory approvals will be obtained through the Vector Core Facility (Core B). In this project, we propose to investigate the hypothesis that the optimal heterologous rAd primeboost regimen will prove safe and highly immunogenic in individuals both in the United States and in the developing world. We further hypothesize that the immunogenicity of these vaccines will not be substantially suppressed by anti-vector immunity present in human populations. To investigate these hypotheses, we propose the following three Specific Aims: 1. To perform a phase I dose-escalation study to assess the safety and immunogenicity of the rAd35k5 vaccine in healthy individuals in the United States; 2. To perform a phase I dose-escalation study to assess the safety and immunogenicity of the rAd49 vaccine in healthy individuals in the United States; and 3. To perform a phase II study to assess the safety and immunogenicity of the heterologous rAd35k5-rAd49 prime-boost regimen in healthy individuals in the developing world.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI066305-04
Application #
7603037
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2008-04-01
Budget End
2009-03-31
Support Year
4
Fiscal Year
2008
Total Cost
$979,976
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02215
Baden, Lindsey R; Karita, Etienne; Mutua, Gaudensia et al. (2016) Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial. Ann Intern Med 164:313-22
Baden, Lindsey R; Liu, Jinyan; Li, Hualin et al. (2015) Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans. J Infect Dis 211:518-28
Baden, Lindsey R; Walsh, Stephen R; Seaman, Michael S et al. (2014) First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002). J Infect Dis 210:1052-61
Baden, Lindsey R; Walsh, Stephen R; Seaman, Michael S et al. (2013) First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001). J Infect Dis 207:240-7
Barouch, Dan H; Whitney, James B; Moldt, Brian et al. (2013) Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503:224-8
Barouch, Dan H; Liu, Jinyan; Peter, Lauren et al. (2013) Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001). J Infect Dis 207:248-56
Stephenson, Kathryn E; SanMiguel, Adam; Simmons, Nathaniel L et al. (2012) Full-length HIV-1 immunogens induce greater magnitude and comparable breadth of T lymphocyte responses to conserved HIV-1 regions compared with conserved-region-only HIV-1 immunogens in rhesus monkeys. J Virol 86:11434-40
Li, Hualin; Rhee, Elizabeth G; Masek-Hammerman, Katherine et al. (2012) Adenovirus serotype 26 utilizes CD46 as a primary cellular receptor and only transiently activates T lymphocytes following vaccination of rhesus monkeys. J Virol 86:10862-5
Handley, Scott A; Thackray, Larissa B; Zhao, Guoyan et al. (2012) Pathogenic simian immunodeficiency virus infection is associated with expansion of the enteric virome. Cell 151:253-66
Bradley, Ritu R; Maxfield, Lori F; Lynch, Diana M et al. (2012) Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions. J Virol 86:1267-72

Showing the most recent 10 out of 43 publications